Sugi Predict

Sugi Predict / Compounds / SCHEMBL282501

SCHEMBL282501

SCHEMBL282501

CSc1nc(Cl)c(C(=O)O)c(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ PPARG P37231 7/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ CYP2C9 P11712 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ CYP2C19 P33261 2/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21640952 0.88 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL900020 0.85 PPARG (0.42) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL4980053 0.84 KMT2A (0.40) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL20067834 0.83 PPARG (0.41) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL3588741 0.83 PPARG (0.41) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
Hydrochloric Acid SCHEMBL16052974 0.81 PPARG (0.40) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL282489 0.81 POLB (0.48) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL4731578 0.79 TSHR (0.43) SMN1; SMN2ALDH1A1KMT2AMEN1PPARG
SCHEMBL28835178 0.78 KMT2A (0.54) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL20067831 0.78 PPARG (0.45) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637461-B2 Compounds for the activation of AMPK PFIZER INC. (US) 2026-05-26 — — US disclosed
WO-2024140431-A1 COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF IONGEN THERAPEUTICS CO., LTD. (CN) 2024-07-04 — — WO disclosed
US-20240182468-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PFIZER (US) 2024-06-06 — — US disclosed
WO-2024084390-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PFIZER INC. (US) 2024-04-25 — — WO disclosed
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 — — EP disclosed
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 — — EP disclosed
CN-109476642-B Compounds and their use for reducing uric acid levels 阿奎斯特有限责任公司 2022-01-25 — — CN disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 — — US disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 — — US disclosed
US-11020397-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-06-01 — — US disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 — — WO disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 — — WO disclosed
US-6995153-B2 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL. CO., LTD. (JP) 2006-02-07 — — US disclosed
US-20050159409-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO. LTD. (JP) 2005-07-21 — — US disclosed
US-20050085469-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 — — US disclosed
EP-1496059-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2005-01-12 — — EP disclosed
EP-1473295-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2004-11-03 — — EP disclosed
US-20040142930-A1 Cyclic compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-07-22 — — US disclosed
US-20030229089-A1 Cyclic compounds TANABE SEIYAKU CO., LTD. (JP) 2003-12-11 — — US disclosed
EP-1277741-A1 CYCLIC COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-01-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085469-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 SMN1; SMN2 4508/4885ALDH1A1 1862/4885MAPK1 252/4885
US-20240182468-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PRKAG1, PRKAG2, PRKAB1 SMN1; SMN2 3953/4885ALDH1A1 1316/4885MAPK1 329/4885
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 SMN1; SMN2 2912/4885ALDH1A1 226/4885MAPK1 4596/4885
US-20050159409-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 SMN1; SMN2 4586/4885ALDH1A1 1993/4885MAPK1 242/4885
US-12637461-B2 Compounds for the activation of AMPK PRKAG1, PRKAB1, PRKAA1 SMN1; SMN2 4197/4885ALDH1A1 1593/4885MAPK1 435/4885
US-20030229089-A1 Cyclic compounds PDE3B, PDE5A, PDE9A SMN1; SMN2 1517/4885ALDH1A1 1341/4885MAPK1 410/4885
US-11020397-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 SMN1; SMN2 2060/4885ALDH1A1 95/4885MAPK1 4687/4885
US-20040142930-A1 Cyclic compounds PDE3B, PDE4A, PDE5A SMN1; SMN2 1584/4885ALDH1A1 1392/4885MAPK1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.